Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, ...

The new suite of capabilities will accelerate development timelines by enabling both monoclonal antibody (mAb) production and ...

As of 2023, the ABC data indicated that in older adults (=65 years), the prevalence of invasive PD attributed to Capvaxive-unique serotypes was more than triple (34.8%) that of PCV20-unique serotypes ...

Syngene International plans to add bioconjugation suite for end-to-end ADC development: Our Bureau, Bengaluru Thursday, October 23, 2025, 15:15 Hrs [IST] Syngene International, a ...

Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological ...

This seemingly small alteration in atomic composition leads to a cascade of differences in chemical properties, reactivity, ...

Australian Oilseeds Holdings Limited (the “Company”) (NASDAQ: COOT), a manufacturer and seller of sustainable edible oils to customers globally, today announced financial ...

Mohawk Industries, Inc. (NYSE: MHK) today announced third quarter 2025 net earnings of $109 million and earnings per share (“EPS”) of $1.75; ...

Bradley Monk, MD, highlights transformative long-term outcomes from the innovaTV trial, showcasing innovative treatments for cervical cancer at ESMO 2025. Bradley Monk, MD, discusses the long-term ...

CDR-Life, Inc., a biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune ...

Chronic malaria exposure has been proposed to modulate immune function, but its long-term effects on antibody-mediated responses to unrelated pathogens remain poorly defined. Whether these effects ...

Baystreet.ca News Commentary – Scientists engineered invisible immune cells in October 2025 that hide from rejection while destroying tumors[1], as antibody drug conjugates expanded ...